Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein

British Journal of Clinical Pharmacology

Volumn 61, Issue 5, 2006, Pages 538-544

  Shimizu, Mikiko ^a   Uno, Tsukasa ^a   Sugawara, Kazunobu ^b   Tateishi, Tomonori ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Diltiazem; Drug interaction; Fexofenadine; Itraconazole; P glycoprotein; Pharmacokinetics

Indexed keywords

DILTIAZEM; FEXOFENADINE; GLYCOPROTEIN P; ITRACONAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TRANSPORT; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DILTIAZEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; ITRACONAZOLE; MALE; P-GLYCOPROTEIN; TERFENADINE; TIME FACTORS;

EID: 33646263124     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02613.x     Document Type: Article

References (32)

1. Mizuno N Niwa T Yotsumoto Y Sugiyama Y Impact of drug transporter studies on drug discovery and development Pharmacol Rev 2003 55 425 61
2. Ayrton A Morgan P Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 2001 31 469 97
3. Lin JH Yamazaki M Role of P-glycoprotein in pharmacokinetics: clinical implications Clin Pharmacokinet 2003 42 59 98
4. Balayssac D Authier N Cayre A Coudore F Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005 156 319 29
5. Cvetkovic M Leake B Fromm MF Wilkinson GR Kim RB OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab Dispos 1999 27 866 71
6. Putnam WS Ramanathan S Pan L Takahashi LH Benet LZ Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells J Pharm Sci 2002 91 2622 35
7. Perloff MD von Moltke LL Greenblatt DJ Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir J Clin Pharmacol 2002 42 1269 74
8. Niemi M Kivisto KT Hofmann U Schwab M Eichelbaum M Fromm MF Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) Br J Clin Pharmacol 2005 59 602 4
9. Shimizu M Fuse K Okudaira K Nishigaki R Maeda K Kusuhara H Sugiyama Y Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans Drug Metab Dispos 2005 33 1477 81
10. Nozawa T Imai K Nezu J Tsuji A Tamai I Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in humans J Pharmacol Exp Ther 2004 308 438 45
11. Dresser GK Bailey DG Leake BF Schwarz UI Dawson PA Freeman DJ Kim RB Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 2002 71 11 20
12. Dresser GK Kim RB Bailey DG Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides Clin Pharmacol Ther 2005 77 170 7
13. Gupta S Banfield C Kantesaria B Marino M Clement R Affrime M Batra V Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study Clin Ther 2001 23 451 66
14. Hamman MA Bruce MA Haehner-Daniels BD Hall SD The effect of rifampin administration on the disposition of fexofenadine Clin Pharmacol Ther 2001 69 114 21
15. Yasui-Furukori N Uno T Sugawara K Tateishi T Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics Clin Pharmacol Ther 2005 77 17 23
16. Kim RB Leake BF Choo EF Dresser GK Kubba SV Schwarz UI Taylor A Xie HG McKinsey J Zhou S Lan LB Schuetz JD Schuetz EG Wilkinson GR Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 2001 70 189 99
17. Drescher S Schaeffeler E Hitzl M Hofmann U Schwab M Brinkmann U Eichelbaum M Fromm MF MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine Br J Clin Pharmacol 2002 53 526 34
18. Venkatakrishnan K von Moltke LL Greenblatt DJ Effects of the antifungal agents on oxidative drug metabolism: clinical relevance Clin Pharmacokinet 2000 38 111 80
19. Jalava KM Partanen J Neuvonen PJ Itraconazole decreases renal clearance of digoxin Ther Drug Monit 1997 19 609 13
20. Lilja JJ Backman JT Laitila J Luurila H Neuvonen PJ Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol Clin Pharmacol Ther 2003 73 192 8
21. Kaukonen KM Olkkola KT Neuvonen PJ Itraconazole increases plasma concentrations of quinidine Clin Pharmacol Ther 1997 62 510 7
22. Jones DR Gorski JC Hamman MA Mayhew BS Rider S Hall SD Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation J Pharmacol Exp Ther 1999 290 1116 25
23. Cornwell MM Pastan I Gottesman MM Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein J Biol Chem 1987 262 2166 70
24. Piepho RW Culbertson VL Rhodes RS Drug interactions with the calcium-entry blockers Circulation 1987 75 V181 94
25. Rosenthal T Ezra D Calcium antagonists. Drug interactions of clinical significance Drug Saf 1995 13 157 87
26. Uno T Yasui-Furukori N Takahata T Sugawara K Tateishi T Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection J Pharm Biomed Anal 2004 35 937 42
27. Shon JH Yoon YR Hong WS Nguyen PM Lee SS Choi YG Cha IJ Shin JG Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism Clin Pharmacol Ther 2005 78 191 201
28. Russell T Stoltz M Weir S Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers Clin Pharmacol Ther 1998 64 612 21
29. Rebbeor JF Senior AE Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form Biochim Biophys Acta 1998 1369 85 93
30. Molden E Christensen H Sund RB Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro Drug Metab Dispos 2000 28 107 9
31. Andrejak M Hary L Andrejak MT Lesbre JP Diltiazem increases steady state digoxin serum levels in patients with cardiac disease J Clin Pharmacol 1987 27 967 70
32. Yoshida A Fujita M Kurosawa N Nioka M Shichinohe T Arakawa M Fukuda R Owada E Ito K Effects of diltiazem on plasma level and urinary excretion of digoxin in healthy subjects Clin Pharmacol Ther 1984 35 681 5